"path number"	"path_id"	"full_path_length.x"	"testable_path_length.x"	"drug_targeted_genes"	"proportion_drug_targeted"	"full_path_length.y"	"testable_path_length.y"	"aberrational_genes"	"proportion_aberrational"	"proportion_of_cohort_w_aberrational_gene_in_path"	"Num_patient_with_aberrational_gene_.s._in_path"	"count_of_aberrational_genes_in_path_cross_cohort"	"max_in_one_gene"	"min_in_one_gene"	"hyperg_p_value"	"hyperg_p_w_FDR"
"1"	1	"Abacavir transmembrane transport"	5	5	5	1	5	5	5	1	0.0531496062992126	27	27	16	1	0	0
"2"	2	"RSK activation"	6	6	6	1	6	6	6	1	0.0551181102362205	28	30	8	1	0	0
"3"	3	"Signaling by FGFR1 amplification mutants"	1	1	1	1	1	1	1	1	0.00196850393700787	1	1	1	1	0	0
"4"	4	"Signaling by FGFR2 amplification mutants"	1	1	1	1	1	1	1	1	0.00590551181102362	3	3	3	3	0	0
"5"	5	"Signaling by FGFR4 mutants"	1	1	1	1	1	1	1	1	0.00984251968503937	5	5	5	5	0	0
"6"	6	"Signalling to ERK5"	2	2	2	1	2	2	2	1	0.0177165354330709	9	9	6	3	0	0
"7"	7	"t(4;14) translocations of FGFR3"	1	1	1	1	1	1	1	1	0.0177165354330709	9	9	9	9	0	0
"8"	8	"Activation of the AP-1 family of transcription factors"	10	10	8	0.8	10	10	10	1	0.0590551181102362	30	32	8	1	0	0
"9"	9	"AKT-mediated inactivation of FOXO1A"	4	4	3	0.75	4	4	4	1	0.031496062992126	16	16	7	2	0	0
"10"	10	"Activation of BIM and translocation to mitochondria"	3	3	2	0.666666666666667	3	3	3	1	0.0078740157480315	4	4	2	1	0	0
"11"	11	"Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex"	5	5	3	0.6	5	5	5	1	0.0196850393700787	10	10	4	1	0	0
"12"	12	"Serotonin receptors"	12	12	7	0.583333333333333	12	12	12	1	0.102362204724409	52	59	9	1	0	0
"13"	13	"DSCAM interactions"	11	11	6	0.545454545454545	11	11	11	1	0.161417322834646	82	92	24	1	0	0
"14"	14	"Activation of PKB"	4	4	2	0.5	4	4	4	1	0.0118110236220472	6	6	3	1	0	0
"15"	15	"Adenosine P1 receptors"	4	4	2	0.5	4	4	4	1	0.015748031496063	8	8	3	1	0	0
"16"	16	"CD28 dependent Vav1 pathway"	12	12	6	0.5	12	12	12	1	0.0826771653543307	42	47	12	1	0	0
"17"	17	"Enzymatic degradation of Dopamine by monoamine oxidase"	2	2	1	0.5	2	2	2	1	0.00393700787401575	2	2	1	1	0	0
"18"	18	"Enzymatic degradation of dopamine by COMT"	2	2	1	0.5	2	2	2	1	0.00393700787401575	2	2	1	1	0	0
"19"	19	"Inhibition of HSL"	2	2	1	0.5	2	2	2	1	0.0118110236220472	6	6	3	3	0	0
"20"	20	"Inhibition of Signaling by Overexpressed EGFR"	2	2	1	0.5	2	2	2	1	0.0393700787401575	20	21	14	7	0	0
"21"	21	"Neurophilin interactions with VEGF and VEGFR"	4	4	2	0.5	4	4	4	1	0.0610236220472441	31	35	12	4	0	0
"22"	22	"Neurotransmitter Clearance In The Synaptic Cleft"	8	8	4	0.5	8	8	8	1	0.0413385826771654	21	22	6	1	0	0
"23"	23	"PDE3B signalling"	2	2	1	0.5	2	2	2	1	0.0118110236220472	6	6	3	3	0	0
"24"	24	"Regulation of PAK-2p34 activity by PS-GAP/RHG10"	2	2	1	0.5	2	2	2	1	0.0196850393700787	10	10	6	4	0	0
"25"	25	"Stimulation of the cell death response by PAK-2p34"	2	2	1	0.5	2	2	2	1	0.015748031496063	8	8	6	2	0	0
"26"	26	"TRKA activation by NGF"	2	2	1	0.5	2	2	2	1	0.0078740157480315	4	4	3	1	0	0
"27"	27	"p75NTR negatively regulates cell cycle via SC1"	6	6	3	0.5	6	6	6	1	0.0255905511811024	13	13	4	1	0	0
"28"	28	"phospho-PLA2 pathway"	2	2	1	0.5	2	2	2	1	0.0216535433070866	11	11	8	3	0	0
"29"	29	"Recycling of bile acids and salts"	15	15	7	0.466666666666667	15	15	15	1	0.125984251968504	64	79	10	1	0	0
"30"	30	"Post NMDA receptor activation events"	35	35	16	0.457142857142857	35	35	34	0.971428571428571	0.354330708661417	180	259	29	0	0.00139498950055716	0.0487640581104277
"31"	31	"CREB phosphorylation through the activation of Ras"	27	27	12	0.444444444444444	27	27	27	1	0.283464566929134	144	200	29	1	0	0
"32"	32	"G2/M DNA damage checkpoint"	9	9	4	0.444444444444444	9	9	9	1	0.100393700787402	51	55	22	1	0	0
"33"	33	"Sema3A PAK dependent Axon repulsion"	16	16	7	0.4375	16	16	16	1	0.208661417322835	106	126	19	2	0	0
"34"	34	"MEK activation"	7	7	3	0.428571428571429	7	7	7	1	0.0807086614173228	41	44	29	1	0	0
"35"	35	"RAF phosphorylates MEK"	7	7	3	0.428571428571429	7	7	7	1	0.0807086614173228	41	44	29	1	0	0
"36"	36	"Activation of NMDA receptor upon glutamate binding and postsynaptic events"	39	39	16	0.41025641025641	39	39	38	0.974358974358974	0.389763779527559	198	304	29	0	0.000656621125588952	0.0241898756031135
"37"	37	"AMPK inhibits chREBP transcriptional activation activity"	5	5	2	0.4	5	5	5	1	0.0216535433070866	11	11	4	1	0	0
"38"	38	"GRB7 events in ERBB2 signaling"	5	5	2	0.4	5	5	5	1	0.0511811023622047	26	26	13	1	0	0
"39"	39	"NGF-independant TRKA activation"	5	5	2	0.4	5	5	5	1	0.0295275590551181	15	16	5	2	0	0
"40"	40	"PKA-mediated phosphorylation of key metabolic factors"	5	5	2	0.4	5	5	5	1	0.0255905511811024	13	13	4	1	0	0
"41"	41	"Downregulation of ERBB2:ERBB3 signaling"	13	13	5	0.384615384615385	13	13	13	1	0.108267716535433	55	59	13	1	0	0
"42"	42	"CD28 dependent PI3K/Akt signaling"	21	21	8	0.380952380952381	21	21	21	1	0.27755905511811	141	162	86	1	0	0
"43"	43	"Negative regulation of the PI3K/AKT network"	8	8	3	0.375	8	8	8	1	0.0688976377952756	35	36	14	1	0	0
"44"	44	"Organic cation transport"	8	8	3	0.375	8	8	8	1	0.0452755905511811	23	23	8	1	0	0
"45"	45	"AKT phosphorylates targets in the nucleus"	9	9	3	0.333333333333333	9	9	9	1	0.0492125984251969	25	25	7	1	0	0
"46"	46	"Activation of TRKA receptors"	6	6	2	0.333333333333333	6	6	6	1	0.031496062992126	16	17	5	1	0	0
"47"	47	"Dopamine clearance from the synaptic cleft"	3	3	1	0.333333333333333	3	3	3	1	0.0118110236220472	6	6	4	1	0	0
"48"	48	"FGFR1c and Klotho ligand binding and activation"	3	3	1	0.333333333333333	3	3	3	1	0.0196850393700787	10	10	5	1	0	0
"49"	49	"GABA A (rho) receptor activation"	3	3	1	0.333333333333333	3	3	3	1	0.0137795275590551	7	7	4	1	0	0
"50"	50	"Inhibition of TSC complex formation by PKB"	3	3	1	0.333333333333333	3	3	3	1	0.0216535433070866	11	11	6	2	0	0
"51"	51	"Interactions of Tat with host cellular proteins"	3	3	1	0.333333333333333	3	3	3	1	0.0177165354330709	9	9	4	2	0	0
"52"	52	"Klotho-mediated ligand binding"	6	6	2	0.333333333333333	6	6	6	1	0.0452755905511811	23	24	6	1	0	0
"53"	53	"Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha"	3	3	1	0.333333333333333	3	3	3	1	0.0255905511811024	13	14	8	3	0	0
"54"	54	"STAT6-mediated induction of chemokines"	3	3	1	0.333333333333333	3	3	3	1	0.015748031496063	8	8	4	2	0	0
"55"	55	"Signalling to STAT3"	3	3	1	0.333333333333333	3	3	3	1	0.0196850393700787	10	10	6	1	0	0
"56"	56	"betaKlotho-mediated ligand binding"	3	3	1	0.333333333333333	3	3	3	1	0.0275590551181102	14	14	6	3	0	0
"57"	57	"CREB phosphorylation through the activation of Adenylate Cyclase"	7	7	2	0.285714285714286	7	7	7	1	0.106299212598425	54	59	24	1	0	0
"58"	58	"CREB phosphorylation through the activation of CaMKII"	15	15	4	0.266666666666667	15	15	15	1	0.167322834645669	85	106	29	1	0	0
"59"	59	"Constitutive Signaling by EGFRvIII"	15	15	4	0.266666666666667	15	15	15	1	0.295275590551181	150	176	86	1	0	0
"60"	60	"Signaling by EGFR in Cancer"	181	181	47	0.259668508287293	181	181	164	0.906077348066298	0.744094488188976	378	894	86	0	0.00101945192726727	0.0366279408679516
"61"	61	"Signaling by EGFRvIII in Cancer"	181	181	47	0.259668508287293	181	181	164	0.906077348066298	0.744094488188976	378	894	86	0	0.00101945192726727	0.0366279408679516
"62"	62	"Signaling by Ligand-Responsive EGFR Variants in Cancer"	181	181	47	0.259668508287293	181	181	164	0.906077348066298	0.744094488188976	378	894	86	0	0.00101945192726727	0.0366279408679516
"63"	63	"Signaling by EGFR"	179	179	46	0.256983240223464	179	179	162	0.905027932960894	0.742125984251969	377	888	86	0	0.00124879098675357	0.0442599099670069
"64"	64	"Signaling by Overexpressed Wild-Type EGFR in Cancer"	179	179	46	0.256983240223464	179	179	162	0.905027932960894	0.742125984251969	377	888	86	0	0.00124879098675357	0.0442599099670069
"65"	65	"CRMPs in Sema3A signaling"	16	16	4	0.25	16	16	16	1	0.181102362204724	92	114	19	1	0	0
"66"	66	"Carnitine synthesis"	4	4	1	0.25	4	4	4	1	0.0118110236220472	6	6	3	1	0	0
"67"	67	"HuR stabilizes mRNA"	8	8	2	0.25	8	8	8	1	0.0688976377952756	35	35	9	1	0	0
"68"	68	"Processing of DNA ends prior to end rejoining"	4	4	1	0.25	4	4	4	1	0.062992125984252	32	35	23	3	0	0
"69"	69	"Proton/oligonucleotide cotransporters"	4	4	1	0.25	4	4	4	1	0.0216535433070866	11	11	5	1	0	0
"70"	70	"Signaling by PDGF"	184	184	46	0.25	184	184	168	0.91304347826087	0.791338582677165	402	1044	86	0	0.000322665267670441	0.0120913259692948
"71"	71	"Signalling by NGF"	287	287	69	0.240418118466899	287	287	256	0.89198606271777	0.84251968503937	428	1409	86	0	0.000903302712909171	0.0327245173157559
"72"	72	"Ras activation uopn Ca2+ infux through NMDA receptor"	17	17	4	0.235294117647059	17	17	17	1	0.238188976377953	121	156	29	1	0	0
"73"	73	"Unblocking of NMDA receptor, glutamate binding and activation"	17	17	4	0.235294117647059	17	17	17	1	0.22244094488189	113	149	29	1	0	0
"74"	74	"Organic cation/anion/zwitterion transport"	13	13	3	0.230769230769231	13	13	13	1	0.0708661417322835	36	42	8	1	0	0
"75"	75	"Apoptotic cleavage of cellular proteins"	38	38	8	0.210526315789474	38	38	37	0.973684210526316	0.391732283464567	199	297	51	0	0.000792768994529625	0.028960814144909
"76"	76	"Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants"	19	19	4	0.210526315789474	19	19	19	1	0.303149606299213	154	185	86	1	0	0
"77"	77	"Centrosome maturation"	72	72	15	0.208333333333333	72	72	68	0.944444444444444	0.446850393700787	227	382	29	0	0.000857787274130883	0.0311619219106787
"78"	78	"Growth hormone receptor signaling"	24	24	5	0.208333333333333	24	24	24	1	0.151574803149606	77	87	9	1	0	0
"79"	79	"Recruitment of mitotic centrosome proteins and complexes"	72	72	15	0.208333333333333	72	72	68	0.944444444444444	0.446850393700787	227	382	29	0	0.000857787274130883	0.0311619219106787
"80"	80	"Disinhibition of SNARE formation"	5	5	1	0.2	5	5	5	1	0.062992125984252	32	35	11	4	0	0
"81"	81	"FGFR1b ligand binding and activation"	5	5	1	0.2	5	5	5	1	0.015748031496063	8	9	3	1	0	0
"82"	82	"Nicotinamide salvaging"	5	5	1	0.2	5	5	5	1	0.0433070866141732	22	23	7	2	0	0
"83"	83	"RAF activation"	5	5	1	0.2	5	5	5	1	0.0669291338582677	34	34	29	1	0	0
"84"	84	"Xenobiotics"	20	20	4	0.2	20	20	20	1	0.118110236220472	60	66	7	1	0	0
"85"	85	"L1CAM interactions"	97	97	19	0.195876288659794	97	97	90	0.927835051546392	0.647637795275591	329	730	30	0	0.0012999190202001	0.0459474814458431
"86"	86	"Axon guidance"	327	327	63	0.192660550458716	327	327	297	0.908256880733945	0.911417322834646	463	2180	30	0	1.06245666511295e-05	0.000446784371494612
"87"	87	"Cytochrome P450 - arranged by substrate type"	60	60	11	0.183333333333333	60	60	58	0.966666666666667	0.312992125984252	159	220	8	0	0.000168217242716096	0.00691815880446344
"88"	88	"CYP2E1 reactions"	11	11	2	0.181818181818182	11	11	11	1	0.0748031496062992	38	41	6	1	0	0
"89"	89	"Import of palmitoyl-CoA into the mitochondrial matrix"	11	11	2	0.181818181818182	11	11	11	1	0.118110236220472	60	63	18	1	0	0
"90"	90	"Nephrin interactions"	22	22	4	0.181818181818182	22	22	22	1	0.372047244094488	189	244	86	2	0	0
"91"	91	"Recruitment of NuMA to mitotic centrosomes"	11	11	2	0.181818181818182	11	11	11	1	0.0984251968503937	50	55	16	1	0	0
"92"	92	"Developmental Biology"	519	519	87	0.167630057803468	519	519	461	0.888246628131021	0.948818897637795	482	2978	86	0	3.89885591121075e-05	0.00161360503214158
"93"	93	"Nonhomologous End-joining (NHEJ)"	6	6	1	0.166666666666667	6	6	6	1	0.0807086614173228	41	45	23	3	0	0
"94"	94	"Release of eIF4E"	6	6	1	0.166666666666667	6	6	6	1	0.0334645669291339	17	18	9	1	0	0
"95"	95	"Synthesis of 15-eicosatetraenoic acid derivatives"	6	6	1	0.166666666666667	6	6	6	1	0.031496062992126	16	16	6	1	0	0
"96"	96	"Anchoring of the basal body to the plasma membrane"	89	89	14	0.157303370786517	89	89	83	0.932584269662921	0.484251968503937	246	439	29	0	0.00114305087790934	0.0408443146284268
"97"	97	"Syndecan interactions"	20	20	3	0.15	20	20	20	1	0.124015748031496	63	78	11	1	0	0
"98"	98	"Glycogen breakdown (glycogenolysis)"	14	14	2	0.142857142857143	14	14	14	1	0.0925196850393701	47	55	11	1	0	0
"99"	99	"Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"100"	100	"Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"101"	101	"Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"102"	102	"Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"103"	103	"Defective CYP19A1 causes Aromatase excess syndrome (AEXS)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"104"	104	"Defective CYP1B1 causes Glaucoma"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"105"	105	"Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"106"	106	"Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"107"	107	"Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"108"	108	"Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"109"	109	"Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"110"	110	"Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"111"	111	"Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"112"	112	"Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"113"	113	"Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"114"	114	"Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"115"	115	"Defective FMO3 causes Trimethylaminuria (TMAU)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"116"	116	"Defective MAOA causes Brunner syndrome (BRUNS)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"117"	117	"Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"118"	118	"Phase 1 - Functionalization of compounds"	78	78	11	0.141025641025641	78	78	73	0.935897435897436	0.356299212598425	181	269	8	0	0.00145790578993799	0.0487640581104277
"119"	119	"Fatty acids"	15	15	2	0.133333333333333	15	15	15	1	0.108267716535433	55	65	8	2	0	0
"120"	120	"Neurotransmitter Receptor Binding And Downstream Transmission In The  Postsynaptic Cell"	140	140	18	0.128571428571429	140	140	128	0.914285714285714	0.647637795275591	329	742	29	0	0.00117502759491417	0.0418725238354548
"121"	121	"Downregulation of ERBB4 signaling"	8	8	1	0.125	8	8	8	1	0.0846456692913386	43	48	22	1	0	0
"122"	122	"Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)"	8	8	1	0.125	8	8	8	1	0.0748031496062992	38	39	7	2	0	0
"123"	123	"Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus"	8	8	1	0.125	8	8	8	1	0.0531496062992126	27	29	10	1	0	0
"124"	124	"Non-integrin membrane-ECM interactions"	42	42	5	0.119047619047619	42	42	41	0.976190476190476	0.427165354330709	217	349	43	0	0.000373033860340821	0.0139388629177747
"125"	125	"Gamma-carboxylation of protein precursors"	9	9	1	0.111111111111111	9	9	9	1	0.0610236220472441	31	34	10	1	0	0
"126"	126	"Removal of aminoterminal propeptides from gamma-carboxylated proteins"	9	9	1	0.111111111111111	9	9	9	1	0.0551181102362205	28	30	10	1	0	0
"127"	127	"Transmission across Chemical Synapses"	201	201	22	0.109452736318408	201	201	187	0.930348258706468	0.72244094488189	367	1027	29	0	5.93947890825675e-06	0.000251383634996002
"128"	128	"Na+/Cl- dependent neurotransmitter transporters"	19	19	2	0.105263157894737	19	19	19	1	0.12007874015748	61	70	10	1	0	0
"129"	129	"Acetylcholine regulates insulin secretion"	10	10	1	0.1	10	10	10	1	0.104330708661417	53	59	21	1	0	0
"130"	130	"E2F-enabled inhibition of pre-replication complex formation"	10	10	1	0.1	10	10	10	1	0.0452755905511811	23	25	6	1	0	0
"131"	131	"IRAK2 mediated activation of TAK1 complex"	10	10	1	0.1	10	10	10	1	0.0551181102362205	28	33	6	1	0	0
"132"	132	"IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation"	10	10	1	0.1	10	10	10	1	0.0551181102362205	28	33	6	1	0	0
"133"	133	"Tryptophan catabolism"	11	11	1	0.0909090909090909	11	11	11	1	0.0728346456692913	37	39	8	1	0	0
"134"	134	"Neuronal System"	280	280	24	0.0857142857142857	280	280	262	0.935714285714286	0.818897637795276	416	1452	29	0	2.21951559353784e-08	9.45511818903479e-07
"135"	135	"Caspase-mediated cleavage of cytoskeletal proteins"	12	12	1	0.0833333333333333	12	12	12	1	0.230314960629921	117	138	51	1	0	0
"136"	136	"Mitotic Telophase/Cytokinesis"	14	14	1	0.0714285714285714	14	14	14	1	0.145669291338583	74	83	25	1	0	0
"137"	137	"repression of WNT target genes"	14	14	1	0.0714285714285714	14	14	14	1	0.0846456692913386	43	48	10	1	0	0
"138"	138	"Generic Transcription Pathway"	483	483	26	0.0538302277432712	483	483	433	0.89648033126294	0.860236220472441	437	2051	86	0	6.3301648870473e-06	0.000267054847500511
"139"	139	"Extracellular matrix organization"	266	266	14	0.0526315789473684	266	266	252	0.947368421052632	0.846456692913386	430	1775	43	0	8.64222915453183e-10	3.69361383327582e-08
"140"	140	"Transmembrane transport of small molecules"	618	618	32	0.0517799352750809	618	618	548	0.886731391585761	0.940944881889764	478	2781	53	0	1.26181727844177e-05	0.000528918810806033
"141"	141	"Chromatin modifying enzymes"	208	208	9	0.0432692307692308	208	208	188	0.903846153846154	0.751968503937008	382	1120	79	0	0.000694056419344058	0.0254257455278898
"142"	142	"Chromatin organization"	208	208	9	0.0432692307692308	208	208	188	0.903846153846154	0.751968503937008	382	1120	79	0	0.000694056419344058	0.0254257455278898
"143"	143	"TRP channels"	25	25	1	0.04	25	25	25	1	0.251968503937008	128	173	18	2	0	0
"144"	144	"SLC-mediated transmembrane transport"	259	259	10	0.0386100386100386	259	259	239	0.922779922779923	0.714566929133858	363	962	23	0	2.69158796917246e-06	0.000114289148940517
"145"	145	"Kinesins"	27	27	1	0.037037037037037	27	27	27	1	0.226377952755905	115	142	16	1	0	0
"146"	146	"ECM proteoglycans"	55	55	2	0.0363636363636364	55	55	53	0.963636363636364	0.484251968503937	246	449	37	0	0.000398998101874604	0.0148665723926186
"147"	147	"Adherens junctions interactions"	30	30	1	0.0333333333333333	30	30	30	1	0.346456692913386	176	252	29	1	0	0
"148"	148	"Stimuli-sensing channels"	98	98	3	0.0306122448979592	98	98	93	0.948979591836735	0.602362204724409	306	642	53	0	7.91260264521032e-05	0.0032644290312751
"149"	149	"Integrin cell surface interactions"	66	66	2	0.0303030303030303	66	66	63	0.954545454545455	0.454724409448819	231	376	20	0	0.000431985990944961	0.0160499667284483
"150"	150	"Ion channel transport"	167	167	5	0.029940119760479	167	167	156	0.934131736526946	0.716535433070866	364	1020	53	0	1.50704890016229e-05	0.000629694853211032
"151"	151	"Elastic fibre formation"	41	41	1	0.024390243902439	41	41	40	0.975609756097561	0.307086614173228	156	212	21	0	0.000450417912820078	0.016687377291986
"152"	152	"Collagen formation"	86	86	2	0.0232558139534884	86	86	83	0.965116279069767	0.606299212598425	308	726	41	0	1.61810584314859e-05	0.000673944936798332
"153"	153	"Amino acid and oligopeptide SLC transporters"	49	49	1	0.0204081632653061	49	49	47	0.959183673469388	0.206692913385827	105	143	7	0	0.0011133604769521	0.0398923915102734
"154"	154	"Glycogen storage diseases"	257	257	5	0.0194552529182879	257	257	232	0.90272373540856	0.746062992125984	379	988	49	0	0.000242345462345139	0.00910757560812489
"155"	155	"Metabolism of carbohydrates"	257	257	5	0.0194552529182879	257	257	232	0.90272373540856	0.746062992125984	379	988	49	0	0.000242345462345139	0.00910757560812489
"156"	156	"Myoclonic epilepsy of Lafora"	257	257	5	0.0194552529182879	257	257	232	0.90272373540856	0.746062992125984	379	988	49	0	0.000242345462345139	0.00910757560812489
"157"	157	"Transport of inorganic cations/anions and amino acids/oligopeptides"	94	94	1	0.0106382978723404	94	94	90	0.957446808510638	0.468503937007874	238	387	23	0	2.85166291771333e-05	0.00118395384213442
"158"	158	"Rho GTPase cycle"	121	121	1	0.00826446280991736	121	121	113	0.933884297520661	0.584645669291339	297	661	34	0	0.000179956308532514	0.00735468766943915
"159"	159	"Signaling by Rho GTPases"	121	121	1	0.00826446280991736	121	121	113	0.933884297520661	0.584645669291339	297	661	34	0	0.000179956308532514	0.00735468766943915
